---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-002256"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2021-10-25T23:59:59+00:00"
generated_at: "2026-06-28T18:26:56.953224+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Clearside's XIPERE for macular edema associated with uveitis; first suprachoroidal therapy

## Summary
- XIPERE (triamcinolone acetonide injectable suspension) is the first FDA-approved therapy for suprachoroidal injection.
- Phase 3 PEACHTREE trial: 47% of XIPERE patients achieved ≥15-letter BCVA improvement vs 16% sham (p<0.01) at Week 24.
- Bausch + Lomb markets XIPERE; expected availability Q1 2022 under Clearside's SCS Microinjector delivery system.
- This is Clearside's first commercial product and the first approved treatment specifically for macular edema associated with uveitis.

## SEC filing metadata
- accession: 0000950170-21-002256
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2021-10-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017021002256/0000950170-21-002256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017021002256/clsd-20211025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-002256
- JSON: https://secwatch.observer/filing/0000950170-21-002256.json
- Plain text: https://secwatch.observer/filing/0000950170-21-002256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.